PURPOSE: To determine the risk of nephrogenic systemic fibrosis (NSF) in a cohort of patients with chronic liver disease. MATERIALS AND METHODS: This retrospective, Institutional Review Board (IRB)-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant study was performed at a single tertiary liver center. The study cohort comprised 1167 patients with chronic liver disease followed in a liver clinic and exposed to gadolinium-based contrast agents (GBCAs) between February 2004 and October 2007. A retrospective review of medical records was performed. For each patient, data were collected on demographics, history of GBCA exposure, presence of purported risk factors for NSF, and histopathological evidence of NSF. RESULTS: Of the 1167 patients with chronic liver disease, 58% (n = 678) had cirrhosis. The patients had a total of 2421 separate GBCA exposures. Fifty-five percent (n = 646) had a single exposure, 19% (n = 218) had two exposures, and 26% (n = 303) had three or more exposures. Seventy-two percent (n = 843) of patients had renal insufficiency, 25 patients (2.1%) had hepatorenal syndrome, 80 patients (6.8%) were in the perioperative liver transplant period, and 49 patients (4.2%) had one or more additional risk factors for NSF. None of the 1167 patients developed NSF. CONCLUSION: Chronic liver disease does not appear to be a significant risk factor for NSF.
PURPOSE: To determine the risk of nephrogenic systemic fibrosis (NSF) in a cohort of patients with chronic liver disease. MATERIALS AND METHODS: This retrospective, Institutional Review Board (IRB)-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant study was performed at a single tertiary liver center. The study cohort comprised 1167 patients with chronic liver disease followed in a liver clinic and exposed to gadolinium-based contrast agents (GBCAs) between February 2004 and October 2007. A retrospective review of medical records was performed. For each patient, data were collected on demographics, history of GBCA exposure, presence of purported risk factors for NSF, and histopathological evidence of NSF. RESULTS: Of the 1167 patients with chronic liver disease, 58% (n = 678) had cirrhosis. The patients had a total of 2421 separate GBCA exposures. Fifty-five percent (n = 646) had a single exposure, 19% (n = 218) had two exposures, and 26% (n = 303) had three or more exposures. Seventy-two percent (n = 843) of patients had renal insufficiency, 25 patients (2.1%) had hepatorenal syndrome, 80 patients (6.8%) were in the perioperative liver transplant period, and 49 patients (4.2%) had one or more additional risk factors for NSF. None of the 1167 patients developed NSF. CONCLUSION:Chronic liver disease does not appear to be a significant risk factor for NSF.
Authors: Martin R Prince; Hong Lei Zhang; Giles H Roditi; Tim Leiner; Walter Kucharczyk Journal: J Magn Reson Imaging Date: 2009-12 Impact factor: 4.813
Authors: Christine U Lee; Christina M Wood; Gina K Hesley; Nelson Leung; Mellena D Bridges; Jeffrey T Lund; Peter U Lee; Mark R Pittelkow Journal: Arch Dermatol Date: 2009-10
Authors: Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein Journal: Ann Intern Med Date: 2020-06-23 Impact factor: 25.391
Authors: Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873
Authors: Thomas Lauenstein; Francisco Ramirez-Garrido; Young Hoon Kim; Sung Eun Rha; Jens Ricke; Sith Phongkitkarun; Joachim Boettcher; Rajan T Gupta; Pornpim Korpraphong; Wiwatana Tanomkiat; Julia Furtner; Peter S Liu; Maren Henry; Jan Endrikat Journal: Invest Radiol Date: 2015-06 Impact factor: 6.016
Authors: Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian B van der Pol; Swapnil Hiremath Journal: Can J Kidney Health Dis Date: 2018-06-12
Authors: Jeffrey C Weinreb; Roger A Rodby; Jerry Yee; Carolyn L Wang; Derek Fine; Robert J McDonald; Mark A Perazella; Jonathan R Dillman; Matthew S Davenport Journal: Kidney Med Date: 2020-11-10
Authors: Henrik J Michaely; Manuela Aschauer; Hannes Deutschmann; Georg Bongartz; Matthias Gutberlet; Ramona Woitek; Birgit Ertl-Wagner; Walter Kucharczyk; Renate Hammerstingl; Francesco De Cobelli; Martin Rosenberg; Thomas Balzer; Jan Endrikat Journal: Invest Radiol Date: 2017-01 Impact factor: 6.016